Abstract:Familial Mediterranean Fever, a monogenic autoinflammatory disease secondary to MEFV gene mutations in the chromosome 16p13, is characterized by recurrent self-limiting attacks of fever, arthritis, aphthous changes in lips and/or oral mucosa, erythema, serositis. It is caused by dysregulation of the inflammasome, a complex intracellular multiprotein structure, commanding the overproduction of interleukin 1. Familial Mediterranean Fever can be associated with other multifactorial autoinflammatory diseases, as vasculitis and Behçet disease.Symptoms frequently start before 20 years of age and are characterized by a more severe phenotype in patients who begin earlier.Attacks consist of fever, serositis, arthritis and high levels of inflammatory reactants: C-reactive protein, erythrocyte sedimentation rate, serum amyloid A associated with leucocytosis and neutrophilia. The symptom-free intervals are of different length.The attacks of Familial Mediterranean Fever can have a trigger, as infections, stress, menses, exposure to cold, fat-rich food, drugs.The diagnosis needs a clinical definition of the disease and a genetic confirmation. An accurate differential diagnosis is mandatory to exclude infective agents, autoimmune diseases, etc.In many patients there is no genetic confirmation of the disease; furthermore, some subjects with the relieve of MEFV mutations, show a phenotype not in line with the diagnosis of Familial Mediterranean Fever. For these reasons, diagnostic criteria were developed, as Tel Hashomer Hospital criteria, the "Turkish FMF Paediatric criteria", the "clinical classification criteria for autoinflammatory periodic fevers" formulated by PRINTO.The goals of the treatment are: prevention of attacks recurrence, normalization of inflammatory markers, control of subclinical inflammation in attacks-free intervals and prevention of medium and long-term complications, as amyloidosis. Colchicine is the first step in the treatment; biological drugs are effective in non-responder patients.The goal of this paper is to give a wide and broad review to general paediatricians on Familial Mediterranean Fever, with the relative diagnostic, clinical and therapeutic aspects.

Clinical Versus Genetic Diagnosis of Familial Mediterranean Fever.

Genotypic Diagnosis of Familial Mediterranean Fever (FMF) Using New Microsatellite Markers: Example of Two Extensive Non-Ashkenazi Jewish Pedigrees.

Mutations in the MEFV Gene in a Large Series of Patients with a Clinical Diagnosis of Familial Mediterranean Fever.

MEFV-Gene Analysis in Armenian Patients with Familial Mediterranean Fever: Diagnostic Value and Unfavorable Renal Prognosis of the M694V Homozygous Genotype—Genetic and Therapeutic Implications

Molecular investigation of MEFV gene polymorphisms among patients with familial mediterranean fever-like symptoms

MEFV Mutations and Phenotype-Genotype Correlations in North African Jews and Armenians with Familial Mediterranean Fever.

The significance of carrying MEFV variants in symptomatic and asymptomatic individuals

Phenotype-genotype correlation in children with familial Mediterranean fever in Morocco

Non-Founder Mutations In The Mefv Gene Establish This Gene As The Cause Of Familial Mediterranean Fever (Fmf)

Unraveling the genome: Familial Mediterranean fever

Localization of the Familial Mediterranean Fever Gene (fmf) to A 250-Kb Interval in Non-Ashkenazi Jewish Founder Haplotypes

Rational Search for Genes in Familial Cortical Myoclonic Tremor with Epilepsy, Clues from Recent Advances.

Genewise detection of variants in MEFV gene using nanopore sequencing

Genetic and Clinical Manifestations of Familial Mediterranean Fever in Children from the Central North of Iran

Implementation of long-read sequencing for routine molecular diagnosis of familial mediterranean fever

Diagnostic delays in familial Mediterranean fever: a Juvenile Inflammatory Rheumatism (JIR) cohort study

‘Silent’ carriage of two familial Mediterranean fever gene mutations in large families with only a single identified patient

FMF is not always "fever": from clinical presentation to "treat to target"

Identification of Disease-Promoting HLA Class I and Protective Class II Modifiers in Japanese Patients with Familial Mediterranean Fever

Comparison of Clinical and Genetic Characteristics of Familial Mediterranean Fever Patients Among Adult Age Groups

E148Q variant: a familial Mediterranean fever-causing mutation or a sequence variant?